Exane Derivatives’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | $106K | Buy |
1,084
+1,081
| +36,033% | +$105K | 0.06% | 260 |
|
|
2022
Q1 | $281 | Hold |
3
| – | – | ﹤0.01% | 926 |
|
|
2021
Q4 | $256 | Hold |
3
| – | – | ﹤0.01% | 809 |
|
|
2021
Q3 | $288 | Hold |
3
| – | – | ﹤0.01% | 973 |
|
|
2021
Q2 | $292 | Hold |
3
| – | – | ﹤0.01% | 978 |
|
|
2021
Q1 | $292 | Hold |
3
| – | – | ﹤0.01% | 825 |
|
|
2020
Q4 | $288 | Sell |
3
-44
| -94% | -$4.22K | ﹤0.01% | 761 |
|
|
2020
Q3 | $4.52K | Hold |
47
| – | – | ﹤0.01% | 488 |
|
|
2020
Q2 | $5.73K | Hold |
47
| – | – | ﹤0.01% | 422 |
|
|
2020
Q1 | $4.07K | Hold |
47
| – | – | ﹤0.01% | 439 |
|
|
2019
Q4 | $5.05K | Sell |
47
-56
| -54% | -$6.01K | ﹤0.01% | 418 |
|
|
2019
Q3 | $9.28K | Sell |
103
-5,000
| -98% | -$450K | ﹤0.01% | 410 |
|
|
2019
Q2 | $431K | Buy |
5,103
+246
| +5% | +$20.8K | 0.08% | 173 |
|
|
2019
Q1 | $428K | Buy |
4,857
+4,372
| +901% | +$385K | 0.08% | 151 |
|
|
2018
Q4 | $34.6K | Buy |
485
+484
| +48,400% | +$34.6K | 0.01% | 368 |
|
|
2018
Q3 | $123 | Sell |
1
-1
| -50% | -$123 | ﹤0.01% | 572 |
|
|
2018
Q2 | $198 | Sell |
2
-23
| -92% | -$2.28K | ﹤0.01% | 552 |
|
|
2018
Q1 | $2.02K | Sell |
25
-140
| -85% | -$11.3K | ﹤0.01% | 419 |
|
|
2017
Q4 | $12.8K | Sell |
165
-640
| -80% | -$49.6K | ﹤0.01% | 350 |
|
|
2017
Q3 | $49.3K | Buy |
+805
| New | +$49.3K | 0.01% | 279 |
|